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Angiotensin-converting enzyme (ACE) inhibitors appear to possess unique cardioprotective
benefits, even when used in patients without high blood pressure or left ventricular
dysfunction (the traditional indications for ACE inhibitor therapy). The ACE inhibitors
improve endothelial function and regress both left ventricular hypertrophy and arterial mass
better than other antihypertensive agents that lower blood pressure equally as well. These
agents promote collateral vessel development and improve prognosis in patients who have had
a coronary revascularization procedure (i.e., percutaneous transluminal coronary angioplasty
and coronary artery bypass graft surgery). Insulin resistance, present not only in type 2
diabetes but also commonly in patients with hypertension or coronary artery disease, or both,
sensitizes the vasculature to the trophic effects of angiotensin II and aldosterone. This may
partly explain the improvement in prognosis noted when patients who have atherosclerosis or
diabetes are treated with an ACE inhibitor. Therapy with ACE inhibitors has also been
shown, in two large, randomized trials, to reduce the incidence of new-onset type 2 diabetes
through largely unknown mechanisms. The ACE inhibitors are safe, well tolerated and
affordable medications. The data suggest that most people with atherosclerosis should be
considered candidates for ACE inhibitor therapy, unless they are intolerant to the medica-
tion, or have systolic blood pressures consistently ,100 mm Hg. Patients who show evidence
of insulin resistance (with or without overt type 2 diabetes) should also be considered as
candidates for prophylactic ACE inhibitor therapy. Although angiotensin receptor blockers
should not be considered equivalent to ACE inhibitors for this indication, they may be a
reasonable alternative for patients intolerant of ACE inhibitors. (J Am Coll Cardiol 2001;37:
1–8) © 2001 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) inhibitors, first in-
troduced almost 20 years ago, have proven effective in the
treatment of hypertension and congestive heart failure
(CHF) (1,2). Recent evidence suggests these agents may
provide protection against adverse cardiovascular events
when used in patients with atherosclerotic cardiovascular
disease without high blood pressure (BP) or left ventricular
(LV) dysfunction (3). The ACE inhibitors also protect
against cardiac events in patients with type 2 diabetes and
insulin resistance (3). Insulin resistance and hyperinsulin-
emia sensitize the cardiovascular system to the adverse
effects of both angiotensin II and aldosterone (4). This
accounts, in part, for the increased prevalence of hyperten-
sion in patients with insulin resistance or type 2 diabetes, as
well as the common occurrence of left ventricular hypertro-
phy (LVH) and diffuse intimal thickening in patients with
insulin resistance, even if they have normal or high normal
BP (5). The ACE inhibitors, by blocking activation of the
renin-angiotensin system, interfere with atherogenesis (6),
favorably remodel the LV and arteries (6) and may improve
the prognosis of patients with atherosclerosis (3). In a large,
randomized, controlled trial of .9,000 patients with estab-
lished atherosclerotic disease, ramipril decreased the occur-
rences of death, myocardial infarction (MI), stroke and
new-onset diabetes (3). The ACE inhibitors are safe, well
tolerated and affordable medications. Should all patients
with coronary artery disease (CAD), stroke or peripheral
arterial disease be started on an ACE inhibitor, even in the
setting of normal BP and normal LV function? Should
patients with diabetes and/or insulin resistance be treated
with ACE inhibitors even before the development of
atherosclerotic cardiovascular disease? How and why do
ACE inhibitors improve the prognosis of CAD? Which
ACE inhibitors are best for these indications? These are
relevant questions with far-reaching implications that clini-
cians are asking in light of novel and compelling data.
The effect of ACE inhibitors on cardiovascular out-
comes. Clues regarding the potential, unique cardioprotec-
tive properties of ACE inhibitors have been noted for
several years. One meta-analysis (1) of .9,000 patients
treated with an ACE inhibitor for depressed LV systolic
function and CHF showed a 23% reduction in the risk of
MI in the patients receiving active therapy. The reduction in
risk appeared to be independent of BP–lowering effects,
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diabetic status, use of other medications, etiology of the
heart failure and left ventricular ejection fraction (LVEF).
To further investigate this unexpected finding, a large,
randomized, controlled trial was performed.
The HOPE study. The Heart Outcomes Prevention Eval-
uation (HOPE) study (3) evaluated the effect of ramipril in
9,297 patients who had either 1) established atherosclerotic
disease (80% of patients had known CAD, 43% had
peripheral vascular disease, 11% had a previous stroke or
transient ischemic attack); or 2) diabetes with at least one
other risk factor (hypertension, elevated total cholesterol,
depressed high density lipoprotein cholesterol, smoking or
microalbuminuria); 38% of the study patients were diabetic.
Patients were excluded from the trial if they had a history of
CHF or an LVEF ,40%. Although hypertension was
present in 47% of patients, BP was controlled with medi-
cations other than ACE inhibitors before enrollment in the
trial. Patients randomly received 10 mg of ramipril or
placebo once a day. The study was stopped prematurely at
41⁄2 years when the ramipril group was noted to have a 22%
reduction (p , 0.001) in the primary outcome: a composite
end point comprised of MI, stroke or death from cardio-
vascular disease. In addition, a significant risk reduction was
noted for most individual end points, such as all-cause
mortality (16%), MI (20%), stroke (32%), cardiac arrest
(37%) and revascularization procedures (15%). Of interest,
the development of new diabetes was reduced by 34% (p ,
0.001) in the ramipril-treated group.
The beneficial effects of ramipril in the HOPE study were
observed consistently among all subgroups, including pa-
tients with and without diabetes, with and without hyper-
tension, older and younger than 65 years of age and with or
without documented CAD (the magnitude of benefit ap-
peared to be similar in the group of patients without
documented CAD, but the sample size was too small to
yield a significant p value), and independent of the effects of
concomitant cardiovascular medications (such as aspirin,
beta-blockers, lipid-lowering agents or other BP agents).
The risk reduction was largely independent of the modest
lowering of BP (23/2 mm Hg) noted with ramipril. The
average BP at baseline for the entire group was
139/79 mm Hg. At the end of the study, the mean systolic
BP of the ramipril group was 136 mm Hg, compared with
139 mm Hg in the placebo group. The reduction in risk
attributable to the ACE inhibitor was apparent by one year
into the study, and the survival curves continue to diverge
throughout the course of the study (Fig. 1).
The impressive benefits found in the HOPE trial oc-
curred despite the fact that 21% of patients in the ramipril-
treated group were not receiving ACE inhibitor therapy by
study end, and 12% of placebo-assigned patients were
taking an ACE inhibitor. The noncompliance rate may have
diluted the results, suggesting that the actual benefit of
ramipril may be even greater than that noted by this
intention-to-treat analysis.
ACE inhibitor therapy for MI. More than 120,000 pa-
tients have been studied in randomized, controlled trials
evaluating the effects of ACE inhibitors during and after
acute MI. A recent meta-analysis of these trials (7) showed
a 7% reduction in 30-day mortality among the patients
assigned to ACE inhibitor therapy. The absolute benefit
was particularly large in high-risk patients, such as those in
Killip class II or III (mild to moderate CHF), heart rate
.100 beats/min, anterior infarction and diabetes (8,9).
ACE inhibitors after revascularization. The QUO
VADIS study (effects of QUinapril On Vascular ACE and
Determinants of ISchemia) enrolled 149 patients undergo-
ing elective coronary artery bypass graft surgery who were
subsequently randomized to receive quinapril 40 mg/day or
placebo at least two weeks before surgery (10); treatment
was continued for one year. Like the HOPE study, patients
in the recently reported QUO VADIS study did not have
traditional indications for an ACE inhibitor (BP was
controlled and LV function was normal). By one year, an
80% reduction in ischemic events (MI, ischemic stroke,
transient ischemic attack or recurrence of angina pectoris)
was noted in the quinapril-treated group. During this study,
18% of placebo-assigned patients and 4% of quinapril-
treated patients (p 5 0.04) experienced ischemic events.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
APRES 5 Angiotensin-converting enzyme inhibition
Post REvascularization Study
ARB 5 angiotensin receptor blocker
BP 5 blood pressure
CAD 5 coronary artery disease
CHF 5 congestive heart failure
HOPE 5 Heart Outcomes Prevention Evaluation study
LV 5 left ventricular, left ventricle
LVEF 5 left ventricular ejection fraction
LVH 5 left ventricular hypertrophy
MI 5 myocardial infarction
PAI-1 5 plasminogen activator inhibitor-1
t-PA 5 tissue plasminogen activator
Figure 1. The occurrence of myocardial infarction, stroke or cardiovascular
death in the HOPE study (5). The ramipril group did substantially better
than the placebo group (relative risk 0.78, 95% confidence interval 0.70 to
0.86).
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The BP levels were similar in the ACE inhibitor and
placebo groups, suggesting the cardioprotection was con-
ferred predominantly through mechanisms other than an
antihypertensive effect.
The Angiotensin-converting enzyme inhibition Post
REvascularization study (APRES) evaluated the effect of
ramipril in 159 patients after elective coronary angioplasty
or bypass surgery with normal BP and moderately reduced
LVEF (between 30% and 50%) but no CHF (11). The
ramipril-treated group experienced a significant reduction in
cardiac death, MI and CHF (risk reduction 58%, p 5 0.03).
All-cause mortality was lower (p 5 0.05) in the ramipril
group also (Fig. 2).
How and why do ACE inhibitors improve prognosis?
The ACE inhibitors exert a myriad of effects on the
cardiovascular system. The relative importance of these
various actions in improving cardiovascular outcomes is
speculative. The ACE inhibitors are moderately effective in
lowering BP. Even mild improvements in BP can positively
influence outcomes. In the HOPE study, the 3 mm Hg
drop in systolic blood pressure should have produced de-
creases of only 13% for stroke (actual reduction 5 32%) and
5% for MI (actual reduction 5 20%) according to World
Health Organization guidelines for hypertension (11a).
Some studies suggest that ACE inhibitors lower the risk of
adverse cardiovascular events more than other classes of
antihypertensive drugs that produce equal or greater drops
in BP (12,13). The unique cardioprotective benefits of ACE
inhibitors are especially apparent in high-risk patients, such
as individuals with both hypertension and diabetes. In two
trials, one that used fosinopril versus felodipine (12) and the
other that used enalapril versus nisoldipine (13), long-term
ACE inhibitor therapy in patients with type 2 diabetes and
hypertension decreased cardiovascular events by almost
50%, compared with calcium channel blocker therapy,
despite equivalent BP reductions. In a recent large observa-
tional cohort study of 52,000 hypertensive patients followed
between 1980 and 1995, those receiving long-term ACE
inhibitor therapy were noted to have a 20% lower all-cause
mortality rate, compared with those using other classes of
BP medications, including calcium channel blockers, diuret-
ics and beta-blockers (14). Hypertension usually coexists
within a cluster of risk factors. The ACE inhibitors not only
lower BP but also positively influence many other aspects of
the atherogenic milieu.
Not all studies support the concept that ACE inhibitors
are superior to other antihypertensive drugs in terms of
event reduction. The CAPtopril Prevention Project
(CAPPP) studied 10,985 hypertensive patients randomized
to receive captopril, 50 mg once or twice daily, versus a
beta-blocker and diuretic (15). Cardiovascular outcomes
were similar during the six-year study. However, the fact
that the combination beta-blocker/diuretic group achieved
lower BP levels than the captopril group almost certainly
influenced the outcomes and limits the clinical relevance of
the findings.
Effects on endothelial function. Endothelial dysfunction
plays a fundamental role in the genesis and development of
a variety of cardiovascular diseases and is the final common
pathway through which most cardiovascular risk factors
contribute to atherosclerosis and inflammation (16). Unlike
most other antihypertensive agents, ACE inhibitors have
been shown to improve endothelium-dependent vasodila-
tion (17). Endothelial health is largely the result of a balance
between angiotensin II and nitric oxide. Angiotensin II is a
powerful vasoconstrictor, which also stimulates mitogenesis
(16), resulting in smooth muscle cell hyperplasia, fibroblas-
tic proliferation and collagen deposition (18), all of which
produce increases in arterial wall mass and reductions in
compliance in both the LV and the vascular system.
Angiotensin II depletes nitric oxide production, generates
toxic vascular prooxidants such as peroxynitrite, stimulates
the release of norepinephrine and enhances production of
endothelin-1 (a potent systemic vasoconstrictor) (16).
Aldosterone is also released in response to increased angio-
tensin II concentrations, which independently increases
myocardial fibrosis and intimal hyperplasia, heightens sym-
pathetic activity and stimulates sodium and water retention
and potassium excretion (19).
To counter these vasoconstrictive, mitogenic and pressor
effects, there is nitric oxide. Healthy endothelium produces
nitric oxide, which promotes vasodilation and inhibits
vascular hypertrophy. Our modern life-style and diet, espe-
cially in a genetically predisposed individual, often result in
shifting of this balance to an angiotensin II/aldosterone
dominance. This disturbance frequently leads to hyperten-
sion, atherosclerosis, MI, stroke, CHF and other adverse
cardiovascular events. The ACE inhibitors reduce angioten-
sin II levels and increase nitric oxide production, both
directly and indirectly by blocking degradation of bradyki-
nin (which stimulates the local release of nitric oxide),
resulting in restoration of more normal endothelial function
(16). Although other antihypertensive medications lower
BP as well or better than ACE inhibitors, they are not as
Figure 2. Survival curves from the APRES study. The ramipril group
experienced significantly fewer adverse cardiovascular events during the
follow-up period (11).
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effective as ACE inhibitors for improving endothelial func-
tion (17,20,21).
Effects on LVH and arterial wall mass. Left ventricular
hypertrophy is one of the strongest independent risk factors
for adverse cardiac events, especially in the elderly popula-
tion (22). In the Framingham population, the presence of
LVH by echocardiographic criteria increased the risk of
sudden death fivefold and the risk of coronary disease
threefold (23). Left ventricular hypertrophy is also a pow-
erful predictor for the development of CHF and life-
threatening ventricular dysrhythmias (22). Regression of
LVH improves these risks. In a recent study using echocar-
diographic techniques, those patients who experienced sig-
nificant LVH regression by antihypertensive therapy had a
75% lower risk of subsequent cardiovascular events over an
eight-year follow-up, compared with those who did not
have regression of LVH (24).
The presence or absence of LVH is only partially ex-
plained by BP levels. Insulin resistance, overt type 2 diabetes
and obesity all act synergistically with elevated BP (espe-
cially systolic pressure or pulse pressure) (25) to result in
LVH (4). Hyperinsulinemia sensitizes the cardiovascular
system to the trophic effects of angiotensin II and aldoste-
rone (19,26). Because angiotensin II and aldosterone stim-
ulate myocyte hypertrophy and increased formation of
extracellular matrix (e.g., collagen) (18), it is not surprising
that ACE inhibitors are the most effective of the antihy-
pertensive medications for the prevention and regression of
LVH (27). The magnitude of this effect is large; one
longitudinal study showed that ACE inhibition reduced LV
mass by ;40% over the course of a three-year study,
bringing the LV mass into a normal range (28).
Hypertension and insulin resistance also promote smooth
muscle hypertrophy, hyperplasia and increased fibrous tissue
deposition in the arterial walls (16). This leads to reduced
arterial compliance and endothelial dysfunction—the milieu
that promotes the genesis and progression of atherosclerotic
plaque. Angiotensin-converting enzyme inhibition facili-
tates the reversal of these processes and the normalization of
arterial wall structure and function (17,18,20,21). However,
a recent randomized study involving 617 patients with
documented atherosclerosis at baseline found no effect of
ramipril on the progression of carotid atherosclerosis over a
four-year period (29). This study, though underpowered to
look at event reduction, showed a 34% decreased risk of
nonfatal MI or coronary heart disease death. Similarly, a
four-year randomized angiographic trial reported that al-
though enalapril did not affect coronary atherosclerotic
progression, it did significantly reduce adverse cardiovascu-
lar events (29a). This suggests that the cardioprotection of
ACE inhibitors is not related to changes in atherosclerotic
progression. Finally, ACE inhibitors appear to augment the
development of collateral blood flow in the myocardium
(30). This action may account for some of the observed
benefit of ACE inhibition in the prevention of MI.
Other potentially beneficial effects of ACE inhibition.
The metabolic effects of ACE inhibitors probably also play
a role in favorably altering cardiovascular outcomes. Insulin
resistance is slightly improved by ACE inhibition, although
the remarkable 34% reduction in the occurrence of new
diabetes during the HOPE study is unlikely to be accounted
for by this mild effect alone (3). In CAPPP, similar results
were reported, with a 14% risk-adjusted decrease in the
incidence of new diabetes in the ACE inhibitor–treated
group over a five-year period. In contrast, beta-blockers and
high dose diuretics worsen insulin resistance and may
increase the risk of developing type 2 diabetes (31). The
lipid profile is unaffected or mildly improved by ACE
inhibitor therapy, unlike many other classes of antihyper-
tensive medications, such as diuretics and beta-blockers,
which modestly worsen most lipid variables.
Fibrinolysis is largely regulated by endothelial expression
of tissue plasminogen activator (t-PA) and plasminogen
activator inhibitor (PAI-1), which is the major physiologic
inhibitor of t-PA. Epidemiologic evidence suggests that
elevated PAI-1 and impaired fibrinolysis are risk factors for
thrombotic cardiovascular events, such as MI and stroke
(32). Levels of PAI-1 are generally elevated in patients with
diabetes, obesity and insulin resistance (32).
The angiotensin-converting enzyme is a crucial mediator
of the interaction between PAI-1 and t-PA (31). Bradyki-
nin stimulates the production and release of t-PA, whereas
angiotensin II is a stimulus for the endothelial production of
PAI-1. Accordingly, activation of the RAS increases PAI-1,
and ACE inhibition decreases it. In one study, ramipril
lowered PAI-1 antigen levels by 44% and PAI-1 activity by
22% (33). Angiotensin II increases platelet aggregation and
promotes oxidative stress of the blood vessel, which upregu-
lates expression of the adhesion molecules that initiate the
inflammatory response mediating atherosclerosis (16). The
clinical relevance of these effects on pathologic vascular
thrombotic events is uncertain so far.
A recent meta-analysis reported a 20% decrease in sudden
death in patients with CHF treated with ACE inhibitors
(34). Ramipril has been shown to decrease QT dispersion
(35), a possible mechanism by which ACE inhibition might
reduce the risk of sudden death.
Is an ACE an ACE? Practical considerations. Are the
benefits of ACE inhibition a “class effect”? Ten ACE
inhibitors are now available on the U.S. market. These
drugs vary greatly with respect to half-life, degree of lipid
solubility, route of elimination, price and tissue levels (Table
1). Head-to-head, long-term outcome studies have not been
performed with the ACE inhibitor class, and thus the issue
regarding benefits of specific agents versus a class effect
remains speculative.
When using this class of drugs for preventing adverse
cardiovascular events, it may be particularly important to
achieve effective ACE inhibition in the tissues of the vessel
wall and the myocardium. Because lipophilicity enhances
tissue penetration, ACE inhibitors with good lipid solubility
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(like ramipril, trandolapril, fosinopril and quinapril) may be
particularly effective for improving prognosis. Ramipril and
trandolapril both have very long half-lives, resulting in
excellent ACE inhibition throughout a 24-h cycle after a
single daily dose. Without question, ramipril possesses the
most impressive clinical data with respect to event reduction
(the HOPE study [5] and others [2,11,35]). Trandolapril
has been shown to improve life expectancy after anterior
infarction by .100% in subgroups of patients with diabetes
or hypertension (36). Quinapril has a relatively short half-
life (2 h), but it does have an active metabolite that remains
in the circulation for an entire 24-h dosing period.
The ACE inhibitor class is not expensive compared with
other classes of modern medications such as the statins. In
an economic substudy of the HOPE trial, the cost per year
of life saved with ramipril was $3,100, or about half the cost
of statins in comparable analyses (37). However, most
patients with CAD are on a growing list of medications, and
often the cumulative cost is burdensome. Table 1 lists the
average wholesale price of the various ACE inhibitors that
are available in the U.S. If cost is a limiting factor, ACE
inhibitors with a flat pricing schedule (whereby all doses
have the same price per unit) offer opportunities for sub-
stantial savings, especially if the pills can be split in half.
The side-effect profile of ACE inhibitors is relatively
benign, and the major limitation relates to a dry, nonpro-
ductive cough (38). All ACE inhibitors seem to exhibit a
similar incidence of this common, troublesome, but non-
pathologic complaint related to increased bradykinin levels
in the lungs. Angioedema occurrs in ;0.1% of patients
treated with ACE inhibitors. Typically, a patient’s creati-
nine will rise ;0.1 mg/dl after initiating ACE inhibition. A
more substantial rise in creatinine can be anticipated in
patients who are dehydrated or in those with significant
renal impairment. It is generally safe to start ACE inhibitor
therapy in patients with a creatine level #3.0 mg/dl. In the
long term, ACE inhibitor therapy has been shown to be the
most effective medication for preventing progressive renal
dysfunction, both for diabetic (39) and nondiabetic (40)
etiologies of renal failure. Therapy with ACE inhibitors
remains “the last best hope” for staving off long-term
end-stage renal disease and dialysis for many patients with
diabetes, hypertension and chronic azotemia, and thus the
increased difficulty of initiating therapy in this setting is
usually worth the trouble. In fact, a recent study of 20,000
people aged $65 years with depressed LV function found
that ACE inhibitor therapy decreased one-year mortality by
37% in those with a creatinine .3.0 mg/dl compared to a
16% reduction in patients with a creatinine of #3.0 mg/dl
(40a). Patients with azotemia should be well hydrated
before starting low-dose ACE inhibitor therapy.
Aspirin and ACE inhibitors. The hypotensive effect of
ACE inhibition is partly attributable to increased synthesis
of vasodilatory prostaglandins such as prostaglandin E2 (38).
Aspirin produces a dose-dependent inhibition of prosta-
glandins, the basis for its anti-inflammatory effect, that
dissipates within 4 to 6 h. Some scientific reports have
suggested that aspirin reduces the beneficial effects of ACE
inhibitor therapy in patients with CHF and in those who
have had an infarction (41,42), whereas other studies
showed no such therapeutic antagonism (43). In the HOPE
study (5), the ramipril benefits were noted despite the fact
that ;75% of patients were receiving aspirin concomitantly.
In any case, this potentially problematic interaction can be
minimized by strategic dosing of the drugs. The full
antiplatelet effects of aspirin can be conferred with 81 to
100 mg/day, a dose too low to interfere substantially with
prostaglandin synthesis, especially if the aspirin is given 8 to
12 h before or after the ACE inhibitor.
The benefits of ACE inhibition are, in part, dose-
dependent, and thus these drugs should be titrated up to
target doses if possible. A four-year study of 3,164 patients
with CHF randomized to either low-dose (5 mg/day) or
high-dose lisinopril (30 mg) showed that the patients who
received the higher dose had an 8% lower incidence of death
and 24% fewer hospital admissions for heart failure (44).
Although ACE inhibitor therapy does confer significant
protection, even at lower doses, full (target) dose therapy
(Table 1) is required for maximal benefit.
Indications for an ACE inhibitor. Should an ACE inhib-
itor be standard therapy for patients with atherosclerotic
disease? For most patients the answer is yes. Table 2 lists
patients likely to benefit from ACE inhibitor therapy and
relative contraindications. Hypertension is very common
among patients with CAD or other manifestations of
atherosclerotic disease. On the basis of long-term outcome
Table 1. Comparative Data on Angiotensin-Converting Enzyme Inhibitors
Drug
Dosing Range
(mg)
Target Dose
(mg/day)
Half-Life
(h)
Target Dose
Price per Month
Maximal Dose
Price per Month
Benazepril 5–40 20 10–11 $26.00 $ 26.00
Captopril 25–50 150 ,2 $89.00 $ 89.00
Enalapril 5–40 20 11 $51.00 $101.00
Fosinopril 10–40 20 11 $28.00 $ 28.00
Lisinopril 5–40 20 13 $30.00 $ 44.00
Moexepril 7.5–30 15 2–9 $21.00 $ 42.00
Perindopril 4–16 8 8–10 $42.00 $ 84.00
Quinapril 5–80 20 2 $31.00 $ 61.00
Ramipril 1.25–20 10 13–17 $36.00 $ 72.00
Trandolapril 1–8 4 16–24 $23.00 $ 46.00
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data, it is clear that either an ACE inhibitor or beta-blocker
should be chosen as the first-line agent for the treatment of
hypertension in patients with CAD (38,45). Many patients
with CAD without documented hypertension have normal
to mildly elevated BP levels. Recent guidelines stress in-
creasingly stringent goals for the target BP (46). Accumu-
lating evidence suggests that the ideal range for systolic BP
is #130 mmHg, and for pulse pressure #50 mmHg (24).
With these goals in mind, most patients with CAD will
need pharmacologic therapy for optimizing BP. An ACE
inhibitor should be either the first or second agent chosen or
used liberally as adjunctive therapy (of note, in the HOPE
study, ramipril was often added to baseline antihypertensive
therapy, including beta-blockers [40%], diuretics [15%] and
calcium channel blockers [46%] (3).
Routine use of ACE inhibitor therapy is also indicated
for most patients with type 2 diabetes or significant insulin
resistance, even if the BP is not elevated. Studies show that
patients with type 2 diabetes without documented coronary
heart disease have a cardiac risk (for myocardial infarction
and cardiac death) as high as patients with established
coronary heart disease without diabetes (5). Extensive data
support the powerful benefits of ACE inhibitor therapy in
patients with diabetes (3). This benefit appears to be present
with or without hypertension. The Hypertension Optimal
Treatment study recently demonstrated that aggressive BP
control (with a target systolic pressure ,130 mm Hg and
diastolic pressure ;80 mm Hg) is especially important for
diabetic patients (47).
The syndrome of risk factor clustering with hypertension,
depressed high-density lipoprotein levels, elevated triglyc-
erides, abdominal obesity and insulin resistance is very
common in patients with coronary heart disease (5). Often,
the BP levels in these patients are in the borderline high
range or only mildly elevated. The insulin resistance syn-
drome gives rise to many features that independently worsen
the prognosis. Because hyperinsulinemia stimulates exag-
gerated responses to angiotensin II and aldosterone, it
predisposes to LVH, endothelial dysfunction, progressive
thickening and hyperplasia of the arterial wall, as well as
elevated PAI-1 levels (4,25,26). Therapy with ACE inhib-
itors has been shown to improve all of the aforementioned
abnormalities. In addition, individuals with insulin resis-
tance are at markedly increased risk for the future develop-
ment of type 2 diabetes as they age (5), and ACE inhibitor
therapy reduces this risk (3,15). For all of these reasons, it is
logical to use ACE inhibitor therapy liberally in patients
who show evidence of insulin resistance (a practical marker
for insulin resistance is a high-density lipoprotein level
,40 mg/dl and a triglyceride level .150 mg/dl) (5).
Patients with very low baseline BP levels often do not
tolerate initiation of an ACE inhibitor. If a patient with
CAD is on other BP–lowering agents like diuretics, calcium
channel blockers and peripheral alpha1 blockers that do not
have inherent cardioprotective actions, these agents should
be discontinued or held to “make room” for an ACE
inhibitor. If BP remains depressed (systolic BP #90 to
110 mm Hg), the patient may not be a good candidate for
ACE inhibitor therapy.
Is an ARB as good as an ACE Inhibitor? Approximately
5% to 10% of patients will not tolerate an ACE inhibitor.
The angiotensin receptor blocker (ARB) class is the logical
alternative for these patients (48). Long-term outcome data
on event reduction comparing ACE inhibitors and ARBs in
the setting of secondary prevention or hypertension are not
available, although several trials are under way. The Evalu-
ation of Losartan In the Elderly (ELITE II) study (49)
compared captopril, 50 mg three times a day, to losartan,
50 mg/day, in 3,152 patients with CHF. The two-year
mortality rates were 15.9% for the captopril group and
17.7% for the losartan group (p 5 0.16). In a recent study,
quinapril (a lipid-soluble ACE inhibitor) was more effective
than losartan (an ARB) or enalapril (an ACE inhibitor with
relatively poor lipid solubility) at improving flow-mediated
vasodilation, a marker of endothelial function (21).
The local release of bradykinin in the tissues stimulates
nitric oxide release (improving endothelial function) and
shifts the t-PA/PAI-1 balance toward fibrinolysis (16).
These actions of ACE inhibitors are not shared by the
ARBs. Whether or not these, or other, differences will
translate into meaningful differences in clinical event reduc-
tion is unknown. What is clear is that the ARBs are
remarkably free from side effects, including the bradykinin-
stimulated ACE inhibitor cough (33). However, there are
compelling data on event reduction for ACE inhibitors but
not for ARBs. At the present time, ARBs should not be
considered equivalent to ACE inhibitors for this indication,
but for patients with an intolerable cough, they are a
reasonable alternative.
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Table 2. Angiotensin-Converting Enzyme Inhibitor Therapy
Indications for ACE Inhibitor Therapy
c CAD without contraindication to ACE inhibitor therapy
c CAD with systolic blood pressure $130 mm Hg
c Type 2 diabetes with or without CAD
c Insulin resistance with systolic blood pressure $130 mm Hg
c CHF and/or left ventricular dysfunction
Contraindications to ACE Inhibitor Therapy
c Systolic blood pressure ,100 mm Hg (especially with
symptomatic hypotension)
c Angioedema due to ACE inhibition therapy
c Intolerable cough
ACE 5 angiotensin-converting enzyme; CAD 5 coronary artery disease; CHF 5
congestive heart failure.
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